Key statistics
On Thursday, Passage Bio Inc (PASG:NSQ) closed at 0.536, 18.85% above the 52 week low of 0.451 set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.52 |
---|---|
High | 0.547 |
Low | 0.5080 |
Bid | 0.5628 |
Offer | 0.57 |
Previous close | 0.5137 |
Average volume | 273.74k |
---|---|
Shares outstanding | 61.77m |
Free float | 61.47m |
P/E (TTM) | -- |
Market cap | 33.11m USD |
EPS (TTM) | -1.17 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
- Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
- Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
- Passage Bio Welcomes Tom Kassberg to Board of Directors
- Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
More ▼